ClinicalTrials.gg
CompletedNCT00402051Updated Feb 17, 2010Results posted

Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Pemetrexed and Cisplatin in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 12 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 8 of them phase 3. Cisplatin · Carcinoma, Non-Small-Cell Lung.

Enrollment
55th of 198
133 · median 58
Started
2006
with 7 others
Phase 2
115 of 213
4 open now
Registered
74th of 213
by date
Lead sponsor
26 of 213
Eli Lilly and Company

Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, this one is the 55th largest by enrollment of the 198 interventional ones that give a count, is one of 8 that started in 2006, is one of 115 in phase 2, and was the 74th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a two-arm, parallel, open-label, Phase 2 multicenter study of pemetrexed as first line combination therapy with either cisplatin or carboplatin in the palliative setting of stage IIIb and IV non-small cell lung cancer patients. Approximately 130 patients will be included in about 15 centers in Germany and randomized to one of the above treatment regimens in a 1:1 ratio. Chemotherapy will be administered over a maximum of six cycles with a standard length of 21 days. Primary objective will be the Progression Free Survival Time of patients as assessed in both treatment arms.

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or histologically confirmed NSCLC Stage IIIb or IV
  • No previous systemic chemotherapy for this cancer
  • At least one uni-dimensionally meeting (RECIST) criteria
  • (ECOG) Performance status of 0 or 1 and adequate organ function
  • Prior radiation therapy allowed but limited to \<25% of the patient's bone marrow

Exclusion criteria

Exclusion Criteria:

  • Serious concomitant systemic disorder or active infection
  • Mild to moderate renal insufficiency, but unable to interrupt salicylates or other nonsteroidal anti-inflammatory drugs
  • Symptomatic central nervous system (CNS) requiring concurrent therapy
  • Presence of third-space fluid collections
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Cisplatin

    Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Pemetrexed + Carboplatin

    Drug: Pemetrexed · Drug: Carboplatin

Interventions

  • 500 mg/m2, intravenous (IV), every 21 days x 6 cycles

    Also known as: LY231514, Alimta

  • 75 mg/m2, intravenous (IV), every 21 days x 6 cycles

  • Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)

    For this study, we used the exponential distribution (assumption done for the calculation of the sample size) to estimate the PFS rate. The PFS rate (%) and the 95% confidence intervals were calculated based on the following formula: exp(-6 λ) ± 1.96 \* exp(-6 λ) \* (-6 λ)/√r. Where λ was calculated based on the Maximum-Likelihood estimator for ln(λ) as given by (Collett 2003): ln(λ) = ln\[ r / ∑ti \] with r = number of patients with events up to 6 months, ti = survival time of patient i (i=1,...,n), event or censored up to 6 months, and n= total number of patients per treatment group.

    Time frame: Randomization to Month 6

Secondary outcomes

  1. Overall Survival

    Defined as the time from randomization to the date of death from any cause.

    Time frame: Randomization to date of death from any cause (up to 1 year)

  2. Number of Participants With Tumor Response (as Basis for Response Rate)

    Best overall response was evaluated using RECIST Criteria which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatment. CR: complete response, disappearance of all target lesions; PR: partial response, 30% decrease in sum of the longest diameter of target lesions; PD: progressive disease, 20% increase in sum of the longest diameter of target lesions; SD: stable disease, small changes not meeting above criteria. Response Rate: number of participants with response(CR+PR)per total population, multiplied by 100 to give a percentage.

    Time frame: Every 6 weeks for 6 months during the treatment period, and every 3 months during the follow-up period, until disease progression

  3. Time to Treatment Failure (TTF)

    Defined as time from randomization to the first date of disease progression, death due to any cause, or early discontinuation of treatment (any reason), whichever occurred first

    Time frame: Randomization to stopping of treatment, progression, death or initiation of further chemotherapy, whichever occurs first (up to 1 year)

  4. Pharmacology Toxicities

    Number of patients experiencing Grade 3 or 4 hematologic and non-hematologic adverse events (AEs) possibly related to study drug or protocol procedures in this study (a subset of those listed in the AE Module). AEs were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). Grade 3 AEs are severe and undesirable; Grade 4 AEs are life-threatening or disabling.

    Time frame: Every 21-day cycle for up to 6 cycles

07

Results

Posted Jan 7, 2010

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + CisplatinPemetrexed + Carboplatin
Started6667
Received treatment6565
Completed2832
Not completed3835
Withdrew: Progressive disease1320
Withdrew: Adverse event114
Withdrew: Physician decision73
Withdrew: Withdrawal by subject33
Withdrew: Death - related to study drug12
Withdrew: Death due to study disease21
Withdrew: Death due to adverse event02
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)

For this study, we used the exponential distribution (assumption done for the calculation of the sample size) to estimate the PFS rate. The PFS rate (%) and the 95% confidence intervals were calculated based on the following formula: exp(-6 λ) ± 1.96 \* exp(-6 λ) \* (-6 λ)/√r. Where λ was calculated based on the Maximum-Likelihood estimator for ln(λ) as given by (Collett 2003): ln(λ) = ln\[ r / ∑ti \] with r = number of patients with events up to 6 months, ti = survival time of patient i (i=1,...,n), event or censored up to 6 months, and n= total number of patients per treatment group.

Time frame:
Randomization to Month 6
Reported as:
Number · percentage
Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)
percentagePemetrexed + CisplatinPemetrexed + Carboplatin
Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)52.8 (40.3 to 65.3)39.3 (27.8 to 50.8)
Statistical analysis
  • Pemetrexed + Cisplatin · 6-month pfs rate: 52.8 · 95% CI 40.3 to 65.3
  • Pemetrexed + Carboplatin · 6-month pfs rate: 39.3 · 95% CI 27.8 to 50.8
SecondaryOverall Survival

Defined as the time from randomization to the date of death from any cause.

Time frame:
Randomization to date of death from any cause (up to 1 year)
Reported as:
Median · months
Overall Survival
monthsPemetrexed + CisplatinPemetrexed + Carboplatin
Overall Survival11.7 (9.2 to 14.9)8.9 (6.0 to 12.2)
SecondaryNumber of Participants With Tumor Response (as Basis for Response Rate)

Best overall response was evaluated using RECIST Criteria which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatment. CR: complete response, disappearance of all target lesions; PR: partial response, 30% decrease in sum of the longest diameter of target lesions; PD: progressive disease, 20% increase in sum of the longest diameter of target lesions; SD: stable disease, small changes not meeting above criteria. Response Rate: number of participants with response(CR+PR)per total population, multiplied by 100 to give a percentage.

Time frame:
Every 6 weeks for 6 months during the treatment period, and every 3 months during the follow-up period, until disease progression
Reported as:
Number · participants
Number of Participants With Tumor Response (as Basis for Response Rate)
participantsPemetrexed + CisplatinPemetrexed + Carboplatin
Partial Response2113
Stable Disease3132
Disease Progression715
Unknown/Not Done65
Statistical analysis
  • Pemetrexed + Cisplatin · Best overall response rate (%): 32.3 · 95% CI 21.2 to 45.1
  • Pemetrexed + Carboplatin · Best overall response rate (%): 20.0 · 95% CI 11.1 to 31.8
SecondaryTime to Treatment Failure (TTF)

Defined as time from randomization to the first date of disease progression, death due to any cause, or early discontinuation of treatment (any reason), whichever occurred first

Time frame:
Randomization to stopping of treatment, progression, death or initiation of further chemotherapy, whichever occurs first (up to 1 year)
Reported as:
Median · months
Time to Treatment Failure (TTF)
monthsPemetrexed + CisplatinPemetrexed + Carboplatin
Time to Treatment Failure (TTF)3.0 (2.3 to 4.6)3.4 (2.3 to 4.8)
SecondaryPharmacology Toxicities

Number of patients experiencing Grade 3 or 4 hematologic and non-hematologic adverse events (AEs) possibly related to study drug or protocol procedures in this study (a subset of those listed in the AE Module). AEs were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). Grade 3 AEs are severe and undesirable; Grade 4 AEs are life-threatening or disabling.

Time frame:
Every 21-day cycle for up to 6 cycles
Reported as:
Number · participants
Pharmacology Toxicities
participantsPemetrexed + CisplatinPemetrexed + Carboplatin
Any Grade 3/4 Toxicity2936
Grade 3/4 Leucopenia812
Grade 3/4 Neutropenia1117
Grade 3/4 Anemia57
Grade 3/4 Thrombocytopenia211
Grade 3/4 Nausea35
Grade 3/4 Vomiting21
Grade 3/4 Fatigue22
Grade 3/4 Anorexia12
Grade 3/4 Urinary Tract Infection02

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin—22/65 (33.8%)61/65 (93.8%)
Pemetrexed + Carboplatin—28/65 (43.1%)59/65 (90.8%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventPemetrexed + CisplatinPemetrexed + Carboplatin
ThrombocytopeniaBlood and lymphatic system disorders0/655/65
AnaemiaBlood and lymphatic system disorders3/653/65
NauseaGastrointestinal disorders2/653/65
PneumoniaInfections and infestations3/652/65
DyspnoeaRespiratory, thoracic and mediastinal disorders0/653/65
Cardiac failureCardiac disorders1/652/65
VomitingGastrointestinal disorders2/652/65
Renal failure acuteRenal and urinary disorders2/651/65
Deep vein thrombosisVascular disorders0/652/65
Anaemia of malignant diseaseBlood and lymphatic system disorders0/651/65
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPemetrexed + CisplatinPemetrexed + Carboplatin
NauseaGastrointestinal disorders42/6527/65
NeutropeniaBlood and lymphatic system disorders18/6525/65
FatigueGeneral disorders25/6524/65
LeukopeniaBlood and lymphatic system disorders17/6524/65
VomitingGastrointestinal disorders24/658/65
AnaemiaBlood and lymphatic system disorders12/6519/65
ThrombocytopeniaBlood and lymphatic system disorders9/6518/65
ConstipationGastrointestinal disorders17/6511/65
AnorexiaMetabolism and nutrition disorders16/6510/65
DyspnoeaRespiratory, thoracic and mediastinal disorders13/6510/65

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Mean62.3 ± 8.4362.4 ± 7.5162.4 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Female231942
Male424688
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Caucasian6565130
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Germany6565130
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
0 - Fully Active404585
1 - Ambulatory, Restricted Strenuous Activity252045
Histopathology
Histopathology(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Squamous Cell Carcinoma121325
Adenocarcinoma384482
Large Cell Carcinoma639
Mixed Cell Carcinoma011
Bronchioalveolar Carcinoma011
NSCLC, Not Otherwise Specified9312
Presence of Bone and Brain Metastases
Presence of Bone and Brain Metastases(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Bone Metastases141125
Brain Metastases213
Smoking Status
Smoking Status(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Never Smoked9716
Past Smoker414283
Current Smoker151631

3 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coswig, D-01640, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt, 65929, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Großhansdorf, D-22927, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halle, D-06120, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, D-21075, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hofheim, D-65719, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Homburg/Saar, 66421, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Immenhausen, D-34376, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04207, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Luebeck, 23538, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55131, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Muenchen, 81664, Germany
09

References and documents

Publications

  • Schuette WH, Groschel A, Sebastian M, Andreas S, Muller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001. Epub 2013 Jan 16. PubMed 23332288 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Dec 2008 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2006
First posted
Nov 22, 2006
Start
Nov 2006
Primary completionActual
Dec 2008
CompletionActual
May 2009
Results first posted
Jan 7, 2010
Last update
Feb 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00402051
First posted
Nov 22, 2006
Start date
Nov 2006
Primary completion
Dec 2008
Completion
May 2009
Results posted
Jan 7, 2010
Last update
Feb 17, 2010

Study contacts

Call 1-877-CTLilly (1-877-285-4559) or 1-317-615-4559 Mon -Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Carboplatin

Start the discussion